Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Neoplasm Metastasis 1

Interventions

Standard of Care 4Radiotherapy 4Oxaliplatin 4tislelizumab 3anlotinib 2Radiation 2Paclitaxel 2Capecitabine 2130-nm albumin-bound paclitaxel 2vedolizumab 1trastuzumab deruxtecan 1trametinib 1toripalimab 1surufatinib 1pembrolizumab 1ivosidenib 1disitamab vedotin 1coenzyme Q10 1cemiplimab 1blinatumomab 1Whole Genome Sequencing 1Ursodeoxycholic Acid 1Ultrasonography 1Tretinoin 1Thymopentin 1Surgical Procedures, Operative 1Sequence Analysis, RNA 1Respiratory Rate 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ivosidenib × Tumor-Agnostic × Clear all
NCT06593548 2024-09-19

Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer

Fudan University

Phase 2 Not yet recruiting
36 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡